{"id":9246,"date":"2020-03-23T10:44:22","date_gmt":"2020-03-23T18:44:22","guid":{"rendered":"http:\/\/www.drugpolicy.ca\/?p=9246"},"modified":"2020-04-17T08:06:33","modified_gmt":"2020-04-17T16:06:33","slug":"faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic","status":"publish","type":"post","link":"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/","title":{"rendered":"FAQ: Class Exemption for  Controlled Substances during COVID-19"},"content":{"rendered":"\n<iframe loading=\"lazy\" class=\"scribd_iframe_embed\" title=\"HC FAQs Class Exemption - Pandemic Final\" src=\"https:\/\/www.scribd.com\/embeds\/452925762\/content?start_page=1&amp;view_mode=scroll&amp;access_key=key-ZXUt4GtSWAN9urzla7pb\" data-auto-height=\"false\" data-aspect-ratio=\"0.7729220222793488\" scrolling=\"no\" id=\"doc_13947\" width=\"100%\" height=\"600\" frameborder=\"0\"><\/iframe>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-background is-style-dots\" style=\"background-color:#ffffff;color:#ffffff\"\/>\n\n\n\n<div class=\"wp-block-button aligncenter\"><a class=\"wp-block-button__link has-background\" href=\"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2020\/03\/HC-FAQs-Class-Exemption-Pandemic-Final.pdf\" style=\"background-color:#c42127\" target=\"_blank\" rel=\"noreferrer noopener\">Download PDF<\/a><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><p style=\"margin-top:30px; text-align:center\"><strong>Click <a href=\"https:\/\/drugpolicy.ca\/covid-19-harm-reduction-resources\/\" target=\"_blank\" rel=\"noreferrer noopener\" aria-label=\"HERE (opens in a new tab)\">HERE<\/a> for more resources<\/strong><\/p><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><p style=\"text-align:center\"><strong>Click <a rel=\"noreferrer noopener\" aria-label=\"HERE (opens in a new tab)\" href=\"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2020\/03\/FRENCH-HC-FAQs-Class-Exemption-Pandemic-Final-FR.pdf\" target=\"_blank\">HERE<\/a> for French version<\/strong><\/p><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The World Health Organization\u2019s declaration on March 11, 2020, that the novel coronavirus (COVID-19) is now a pandemic and has marked a significant shift in the response from communities across Canada and at all levels of government.<br> <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In response to this evolving health risk, the Office of Controlled Substances has issued a short-term subsection 56(1) exemption from the Controlled Drugs and Substances Act in the public interest. This exemption authorizes pharmacists to prescribe, sell, or provide controlled substances in limited circumstances, or transfer prescriptions for controlled substances.<\/p>\n\n\n\n<div class=\"widget signup-widget mb-5\">\r\n<p class=\"lead\"><strong>\u00cates-vous pr\u00eat(e) \u00e0 aider ?<\/strong><\/p>\r\n<p>Soutenez des politiques sur les drogues bas\u00e9es sur la justice sociale, la compassion et les preuves. Inscrivez-vous \u00e0 notre newsletter pour obtenir des mises \u00e0 jour et d\u00e9couvrez comment vous pouvez agir avec nous.<\/p>\r\n<!-- form.123formbuilder.com script begins here --><script type=\"text\/javascript\" defer=\"defer\" src=\"https:\/\/form.123formbuilder.com\/embed\/6415583.js\" data-role=\"form\" data-default-width=\"650px\"><\/script><!-- form.123formbuilder.com script ends here -->\r\n<\/div>\r\n","protected":false},"excerpt":{"rendered":"<p>In response to this evolving health risk, the Office of Controlled Substances has issued a short-term subsection 56(1) exemption from the Controlled Drugs and Substances Act in the public interest. <\/p>\n","protected":false},"author":38,"featured_media":9254,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_crdt_document":"","footnotes":""},"categories":[1120],"tags":[1124],"class_list":["post-9246","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid-research","tag-safe-supply-oat-and-ioat"],"acf":[],"mb":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FAQ: Class Exemption for Controlled Substances during COVID-19 - Canadian Drug Policy Coalition<\/title>\n<meta name=\"description\" content=\"In response to this evolving health risk, the Office of Controlled Substances has issued a short-term subsection 56(1) exemption from the Controlled Drugs and Substances Act in the public interest.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FAQ: Class Exemption for Controlled Substances during COVID-19 - Canadian Drug Policy Coalition\" \/>\n<meta property=\"og:description\" content=\"In response to this evolving health risk, the Office of Controlled Substances has issued a short-term subsection 56(1) exemption from the Controlled Drugs and Substances Act in the public interest.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Drug Policy Coalition\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-23T18:44:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-17T16:06:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-23-at-11.32.45-AM.png\" \/>\n\t<meta property=\"og:image:width\" content=\"803\" \/>\n\t<meta property=\"og:image:height\" content=\"557\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Canadian Drug Policy Coalition\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Canadian Drug Policy Coalition\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\\\/\"},\"author\":{\"name\":\"Canadian Drug Policy Coalition\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/c32110f234bdb1f5d978710b6b406a30\"},\"headline\":\"FAQ: Class Exemption for Controlled Substances during COVID-19\",\"datePublished\":\"2020-03-23T18:44:22+00:00\",\"dateModified\":\"2020-04-17T16:06:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\\\/\"},\"wordCount\":105,\"publisher\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Screen-Shot-2020-03-23-at-11.32.45-AM.png\",\"keywords\":[\"safe supply OAT and iOAT\"],\"articleSection\":[\"covid research\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\\\/\",\"url\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\\\/\",\"name\":\"FAQ: Class Exemption for Controlled Substances during COVID-19 - Canadian Drug Policy Coalition\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Screen-Shot-2020-03-23-at-11.32.45-AM.png\",\"datePublished\":\"2020-03-23T18:44:22+00:00\",\"dateModified\":\"2020-04-17T16:06:33+00:00\",\"description\":\"In response to this evolving health risk, the Office of Controlled Substances has issued a short-term subsection 56(1) exemption from the Controlled Drugs and Substances Act in the public interest.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\\\/#primaryimage\",\"url\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Screen-Shot-2020-03-23-at-11.32.45-AM.png\",\"contentUrl\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Screen-Shot-2020-03-23-at-11.32.45-AM.png\",\"width\":803,\"height\":557},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FAQ: Class Exemption for Controlled Substances during COVID-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\",\"name\":\"Canadian Drug Policy Coalition\",\"description\":\"Change policy. Save lives.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#organization\",\"name\":\"Canadian Drug Policy Coalition\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/drugpolicy.ca\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/CDPC-logo-white-on-red-150-dpi.jpg\",\"contentUrl\":\"https:\\\/\\\/drugpolicy.ca\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/CDPC-logo-white-on-red-150-dpi.jpg\",\"width\":332,\"height\":333,\"caption\":\"Canadian Drug Policy Coalition\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/c32110f234bdb1f5d978710b6b406a30\",\"name\":\"Canadian Drug Policy Coalition\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g\",\"caption\":\"Canadian Drug Policy Coalition\"},\"description\":\"Advocating for public health- and human rights-based drug policy grounded in evidence, compassion, and social justice\",\"url\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/author\\\/canadian-drug-policy-coalition\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FAQ: Class Exemption for Controlled Substances during COVID-19 - Canadian Drug Policy Coalition","description":"In response to this evolving health risk, the Office of Controlled Substances has issued a short-term subsection 56(1) exemption from the Controlled Drugs and Substances Act in the public interest.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/","og_locale":"fr_FR","og_type":"article","og_title":"FAQ: Class Exemption for Controlled Substances during COVID-19 - Canadian Drug Policy Coalition","og_description":"In response to this evolving health risk, the Office of Controlled Substances has issued a short-term subsection 56(1) exemption from the Controlled Drugs and Substances Act in the public interest.","og_url":"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/","og_site_name":"Canadian Drug Policy Coalition","article_published_time":"2020-03-23T18:44:22+00:00","article_modified_time":"2020-04-17T16:06:33+00:00","og_image":[{"width":803,"height":557,"url":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-23-at-11.32.45-AM.png","type":"image\/png"}],"author":"Canadian Drug Policy Coalition","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Canadian Drug Policy Coalition"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/#article","isPartOf":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/"},"author":{"name":"Canadian Drug Policy Coalition","@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/person\/c32110f234bdb1f5d978710b6b406a30"},"headline":"FAQ: Class Exemption for Controlled Substances during COVID-19","datePublished":"2020-03-23T18:44:22+00:00","dateModified":"2020-04-17T16:06:33+00:00","mainEntityOfPage":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/"},"wordCount":105,"publisher":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#organization"},"image":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/#primaryimage"},"thumbnailUrl":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-23-at-11.32.45-AM.png","keywords":["safe supply OAT and iOAT"],"articleSection":["covid research"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/","url":"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/","name":"FAQ: Class Exemption for Controlled Substances during COVID-19 - Canadian Drug Policy Coalition","isPartOf":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/#primaryimage"},"image":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/#primaryimage"},"thumbnailUrl":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-23-at-11.32.45-AM.png","datePublished":"2020-03-23T18:44:22+00:00","dateModified":"2020-04-17T16:06:33+00:00","description":"In response to this evolving health risk, the Office of Controlled Substances has issued a short-term subsection 56(1) exemption from the Controlled Drugs and Substances Act in the public interest.","breadcrumb":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/#primaryimage","url":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-23-at-11.32.45-AM.png","contentUrl":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-23-at-11.32.45-AM.png","width":803,"height":557},{"@type":"BreadcrumbList","@id":"https:\/\/new.drugpolicy.ca\/fr\/faq-class-exemption-for-patients-practitioners-and-pharmacists-prescribing-and-providing-controlled-substances-in-canada-during-the-coronavirus-pandemic\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.drugpolicy.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"FAQ: Class Exemption for Controlled Substances during COVID-19"}]},{"@type":"WebSite","@id":"https:\/\/www.drugpolicy.ca\/fr\/#website","url":"https:\/\/www.drugpolicy.ca\/fr\/","name":"Canadian Drug Policy Coalition","description":"Change policy. Save lives.","publisher":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.drugpolicy.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.drugpolicy.ca\/fr\/#organization","name":"Canadian Drug Policy Coalition","url":"https:\/\/www.drugpolicy.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2019\/04\/CDPC-logo-white-on-red-150-dpi.jpg","contentUrl":"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2019\/04\/CDPC-logo-white-on-red-150-dpi.jpg","width":332,"height":333,"caption":"Canadian Drug Policy Coalition"},"image":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/person\/c32110f234bdb1f5d978710b6b406a30","name":"Canadian Drug Policy Coalition","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g","caption":"Canadian Drug Policy Coalition"},"description":"Advocating for public health- and human rights-based drug policy grounded in evidence, compassion, and social justice","url":"https:\/\/new.drugpolicy.ca\/fr\/author\/canadian-drug-policy-coalition\/"}]}},"mfb_rest_fields":["title","yoast_head","yoast_head_json"],"_links":{"self":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts\/9246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/comments?post=9246"}],"version-history":[{"count":13,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts\/9246\/revisions"}],"predecessor-version":[{"id":9262,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts\/9246\/revisions\/9262"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/media\/9254"}],"wp:attachment":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/media?parent=9246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/categories?post=9246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/tags?post=9246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}